core laboratories - CLB
CLB
Close Chg Chg %
21.13 0.34 1.61%
Open Market
21.47
+0.34 (1.61%)
Volume: 50.00K
Last Updated:
Nov 22, 2024, 11:43 AM EDT
Company Overview: core laboratories - CLB
CLB Key Data
| Open $21.17 | Day Range 21.10 - 21.70 |
| 52 Week Range 13.82 - 25.13 | Market Cap $991.59M |
| Shares Outstanding 46.95M | Public Float 46.53M |
| Beta 2.36 | Rev. Per Employee N/A |
| P/E Ratio 32.52 | EPS $0.65 |
| Yield 18.94% | Dividend $0.01 |
| EX-DIVIDEND DATE Nov 4, 2024 | SHORT INTEREST N/A |
| AVERAGE VOLUME 322.06K |
CLB Performance
| 1 Week | 8.14% | ||
| 1 Month | 8.70% | ||
| 3 Months | 14.97% | ||
| 1 Year | 14.10% | ||
| 5 Years | -54.22% |
CLB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
7
Full Ratings ➔
About core laboratories - CLB
Core Laboratories Inc. provides proprietary and patented reservoir description and production enhancement services. The company was founded on May 1, 2023 and is headquartered in Houston, TX.
CLB At a Glance
Core Laboratories Inc.
6316 Windfern Road
Houston, Texas 77040
| Phone | 1-713-328-2673 | Revenue | 509.79M | |
| Industry | Oil & Gas Production | Net Income | 36.68M | |
| Sector | Energy Minerals | 2023 Sales Growth | 4.095% | |
| Fiscal Year-end | 12 / 2024 | Employees | 3,600 | |
| View SEC Filings |
CLB Valuation
| P/E Current | 31.27 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 22.48 |
| Price to Sales Ratio | 1.646 |
| Price to Book Ratio | 3.681 |
| Price to Cash Flow Ratio | 33.856 |
| Enterprise Value to EBITDA | 15.013 |
| Enterprise Value to Sales | 2.049 |
| Total Debt to Enterprise Value | 0.206 |
CLB Efficiency
| Revenue/Employee | 141,608.333 |
| Income Per Employee | 10,187.50 |
| Receivables Turnover | 4.142 |
| Total Asset Turnover | 0.875 |
CLB Liquidity
| Current Ratio | 2.533 |
| Quick Ratio | 1.719 |
| Cash Ratio | 0.172 |
CLB Profitability
| Gross Margin | 18.449 |
| Operating Margin | 10.551 |
| Pretax Margin | 8.006 |
| Net Margin | 7.194 |
| Return on Assets | 6.297 |
| Return on Equity | 17.931 |
| Return on Total Capital | 8.331 |
| Return on Invested Capital | 8.891 |
CLB Capital Structure
| Total Debt to Total Equity | 95.805 |
| Total Debt to Total Capital | 48.929 |
| Total Debt to Total Assets | 36.73 |
| Long-Term Debt to Equity | 91.279 |
| Long-Term Debt to Total Capital | 46.617 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Core Laboratories - CLB
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 487.27M | 470.25M | 489.74M | 509.79M | |
Sales Growth
| -27.08% | -3.49% | +4.14% | +4.10% | |
Cost of Goods Sold (COGS) incl D&A
| 395.63M | 386.41M | 410.82M | 415.74M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 20.87M | 18.52M | 17.16M | 15.78M | |
Depreciation
| 19.73M | 17.75M | 16.48M | 15.29M | |
Amortization of Intangibles
| 1.14M | 762.00K | 685.00K | 490.00K | |
COGS Growth
| -23.65% | -2.33% | +6.32% | +1.20% | |
Gross Income
| 91.63M | 83.84M | 78.92M | 94.05M | |
Gross Income Growth
| -38.92% | -8.50% | -5.87% | +19.17% | |
Gross Profit Margin
| +18.81% | +17.83% | +16.11% | +18.45% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 34.03M | 44.17M | 38.12M | 40.26M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 34.03M | 44.17M | 38.12M | 40.26M | |
SGA Growth
| -29.13% | +29.79% | -13.71% | +5.62% | |
Other Operating Expense
| - | - | - | 10.38M | - |
Unusual Expense
| 123.38M | (2.24M) | (669.00K) | 1.69M | |
EBIT after Unusual Expense
| (76.15M) | 41.90M | 41.47M | 52.10M | |
Non Operating Income/Expense
| (1.45M) | 3.30M | (241.00K) | 2.14M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 13.70M | 9.15M | 11.57M | 13.43M | |
Interest Expense Growth
| -6.72% | -33.21% | +26.42% | +16.08% | |
Gross Interest Expense
| 13.70M | 9.15M | 11.57M | 13.43M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (91.30M) | 36.05M | 29.66M | 40.82M | |
Pretax Income Growth
| -211.64% | +139.48% | -17.72% | +37.61% | |
Pretax Margin
| -18.74% | +7.67% | +6.06% | +8.01% | |
Income Tax
| 5.90M | 15.89M | 10.30M | 4.19M | |
Income Tax - Current - Domestic
| 17.73M | 9.18M | 10.95M | 15.25M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| (11.83M) | 6.71M | (657.00K) | (11.06M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (97.07M) | 20.22M | 19.66M | 37.03M | |
Minority Interest Expense
| 140.00K | 492.00K | 205.00K | 350.00K | |
Net Income
| (97.21M) | 19.73M | 19.45M | 36.68M | |
Net Income Growth
| -203.25% | +120.29% | -1.39% | +88.53% | |
Net Margin Growth
| -19.95% | +4.19% | +3.97% | +7.19% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (97.21M) | 19.73M | 19.45M | 36.68M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (97.21M) | 19.73M | 19.45M | 36.68M | |
EPS (Basic)
| -2.1857 | 0.4288 | 0.4198 | 0.7856 | |
EPS (Basic) Growth
| -203.51% | +119.62% | -2.10% | +87.14% | |
Basic Shares Outstanding
| 44.48M | 46.01M | 46.33M | 46.68M | |
EPS (Diluted)
| -2.1857 | 0.4225 | 0.4155 | 0.7717 | |
EPS (Diluted) Growth
| -204.19% | +119.33% | -1.66% | +85.73% | |
Diluted Shares Outstanding
| 44.48M | 46.69M | 46.81M | 47.52M | |
EBITDA
| 68.09M | 58.18M | 57.96M | 69.57M | |
EBITDA Growth
| -45.36% | -14.55% | -0.38% | +20.03% | |
EBITDA Margin
| +13.97% | +12.37% | +11.84% | +13.65% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 20.167 | |
| Number of Ratings | 7 | Current Quarters Estimate | 0.226 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.885 | |
| Last Quarter’s Earnings | 0.25 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.80 | Next Fiscal Year Estimate | 1.032 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 5 | 5 | 7 |
| Mean Estimate | 0.23 | 0.23 | 0.89 | 1.03 |
| High Estimates | 0.26 | 0.25 | 0.92 | 1.21 |
| Low Estimate | 0.20 | 0.18 | 0.84 | 0.82 |
| Coefficient of Variance | 8.11 | 11.69 | 3.31 | 12.39 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 0 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 3 | 3 | 5 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 2 | 2 | 2 |
| MEAN | Hold | Hold | Underweight |
SEC Filings for Core Laboratories - CLB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Core Laboratories - CLB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Oct 4, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 11,296 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.21 per share | 216,996.16 |
| Oct 4, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 11,572 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 4, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 2,850 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 4, 2024 | Hang Teo Sow CAO & Treasurer | 7,063 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $19.21 per share | 135,680.23 |
| Oct 4, 2024 | Hang Teo Sow CAO & Treasurer | 7,162 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Oct 4, 2024 | Hang Teo Sow CAO & Treasurer | 8,995 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 3, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 10,498 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $15.71 per share | 164,923.58 |
| May 3, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 10,577 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 3, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 3,920 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 3, 2024 | Mark Damian Tattoli SVP, Gen Counsel & Secretary | 4,170 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 16, 2024 | Kevin G. Daniels CAO & Treasurer | 8,882 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Christopher S. Hill SVP & CFO | 79,442 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Gwendolyn Y. Gresham SVP | 38,002 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 16, 2024 | Lawrence V. Bruno Chairman and CEO; Director | 234,124 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 5, 2023 | Kevin G. Daniels CAO & Treasurer | 8,803 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Dec 5, 2023 | Kevin G. Daniels CAO & Treasurer | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |